Cont.

50. (new) The pharmaceutical composition of claim 49 wherein the amount

of DCL is from about 0.1 mg to about 5 mg.

51. (new) The pharmaceutical composition of claim 48 which further comprises a pharmaceutically acceptable carrier or excipient.

- 52. (new) The pharmaceutical composition of claim 48 wherein said composition is adapted for oral delivery.
- 53. (new) The pharmaceutical composition of claim 48 wherein said composition is adapted for parenteral, rectal or transdermal delivery.

harmaceutically acceptable salt thereof, and pseudoephedrine.

55. (new) A pharmaceutical composition which comprises DCL, or a pharmaceutically acceptable salt thereof, and acetylsalicylic acid.

56. (new) A pharmaceutical composition which comprises DCL, or a pharmaceutically acceptable salt thereof, and acetaminophen.

57 (new) A pharmaceutical composition which comprises DCL, or a pharmaceutically acceptable salt thereof, and ibuprofen

58. (new) A pharmaceutical composition which comprises DCL, or a pharmaceutically acceptable salt thereof, and ketoprofen.

59. (new) A pharmaceutical composition which comprises DCL, or a pharmaceutically acceptable salt thereof, and naproxen.

60. (new) The pharmaceutical composition of claims 54, 55, 56, 57, 58 or 59 wherein said DCL is present in an amount from about 0.1 mg to about 10 mg.

61. (new) The pharmaceutical composition of claim 54, 55, 56, 57, 58 or 59) wherein said composition is adapted for oral delivery.

Misi